Jun 16, 2020
Biohaven Presents NURTEC(TM) (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
Jun 15, 2020
AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
Apr 27, 2020
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC(TM) ODT in the Middle East
Apr 02, 2020
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists' Prelaunch Expectations that Biohaven's Nurtec ODT Would Challenge Allergan's Ubrelvy and Eli Lilly's Reyvow
Mar 25, 2020
2020 Insights into Calcitonin Gene Related Peptide Type 1 Receptor - Featuring Adepthera, Allergan and Amgen Among Others
Feb 27, 2020
Biohaven's NURTEC(TM) ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults
Dec 18, 2019
Amgen/Novartis' Aimovig Label Revision and Teva's Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly's Emgality in the US Migraine Prevention Market, According to Spherix Global Insights
Sep 26, 2019
Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class Surpassing Teva's Ajovy
Sep 11, 2019
Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
Sep 10, 2019
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Aug 07, 2019
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
Jul 01, 2019
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
May 07, 2019
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
May 03, 2019
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
May 02, 2019
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
May 02, 2019
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio
Apr 03, 2019
Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
Apr 01, 2019
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
Mar 25, 2019
Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success
Feb 04, 2019
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist